A new device to help severe heart failure patients prepare for an artificial heart pump
Cell Directed Immunomodulation Therapy as a Bridge to Left Ventricular Device Implantation in Chronic Heart Failure Patients
This project is testing a special device to help very sick heart failure patients become strong enough for a life-saving artificial heart pump.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Innovative Biotherapies, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11078730 on NIH RePORTER |
What this research studies
Chronic heart failure can be a very serious condition, often involving inflammation that makes the heart weaker. For patients with the most severe form, there aren't many good treatment options, especially when they need an artificial heart pump (LVAD) but are too sick to get one. This project is exploring a new device that works outside the body to help calm down this inflammation. By doing so, we hope to improve heart or kidney function, making it possible for these patients to safely receive an LVAD.
Who could benefit from this research
Good fit: This approach is for patients with very severe, chronic heart failure who are currently too sick to receive a life-saving artificial heart pump.
Not a fit: Patients with less severe heart failure or those who are already eligible for an artificial heart pump would likely not be candidates for this specific treatment.
Why it matters
Potential benefit: If successful, this device could offer a new way to stabilize very ill heart failure patients, potentially extending their lives and allowing them to receive a critical artificial heart pump.
How similar studies have performed: This is an innovative approach, and the current work aims to establish its safety and probable benefit in this patient population.
Where this research is happening
Ann Arbor, United States
- Innovative Biotherapies, INC. — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Johnston, Kimberly Anne — Innovative Biotherapies, INC.
- Study coordinator: Johnston, Kimberly Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.